Navigation Links
Sinovac Reports Fourth Quarter and Full Year 2007 Financial Results
Date:3/30/2008

325,000 for 2006. The R&D expenses recognized as a reduction to government grants were $844,000 for 2007, compared to $845,000 for 2006.

Operating income was $13.5 million for the full year 2007, compared to $440,000 for 2006. The year-over-year increase in operating income reflected the significant increase in vaccine sales.

Net income for the twelve months ended December 31, 2007 was $7.7 million, or $0.19 per diluted share, compared to a net loss of $696,000, or $0.02 per diluted share, for 2006. Net income for 2007 included $478,000 of interest and financing expenses, $2.0 million of income taxes, and $3.6 million of minority interest. Net income for 2006 included $319,000 of interest and financing expenses, $101,000 of income taxes, and $1.0 million of minority interest.

As of December 31, 2007, Sinovac's cash and cash equivalents totaled $17.1 million, compared to $9.2 million as of December 31, 2006.

Fourth Quarter 2007

For the fourth quarter 2007, sales increased 49% to $9.2 million, compared to $6.2 million in the fourth quarter 2006. The growth was attributable to strong sales of the Company's inactivated hepatitis A vaccine, Healive(R), and ongoing marketing initiatives in support of the Company's seasonal influenza vaccine, Anflu(R).

Gross profit for fourth quarter of 2007 was $6.3 million, with a gross margin of 68.3%, compared to $4.9 million and 78.9%, respectively, for the same period of 2006. The lower gross margin resulted primarily from lower margin sales of Anflu(R).

Total operating expenses for the fourth quarter of 2007 decreased to $3.0 million, compared to $4.3 million in the same period of 2006. Selling, general and administrative expenses for fourth quarter of 2007 were $2.5 million, compared to $4.0 million in the same period of 2006. The year-over-year decrease in SG&A expenses was attributable primarily to the partial reversal of bad debt provision in the fourth quarter of 2007 based on th
'/>"/>

SOURCE Sinovac Biotech Co., Ltd.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Sinovac Announces Postponement of Annual General Meeting
2. Sinovac Requests Extension for Annual Shareholders Meeting
3. Sinovac Reports Top-Line Preliminary Phase II Results of Pandemic Influenza (H5N1) Whole Viron Vaccine
4. Sinovac Closes $9.75 Million Private Placement
5. Sinovac Biotech Ltd. Schedules 2007 Annual Meeting of Shareholders
6. Sinovac Announces Adjournment of Annual General Meeting
7. Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2007 Financial Results
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. QMed, Inc. Reports July Medicare SNP Enrollments
10. Phlo Affiliate Reports Expanded Coverage to Oregon Border
11. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/17/2013)... LONDON and BOSTON , June ... market is set to reach $127 billion by 2018, accounting ... to the recently released Orphan Drug Report 2013 ... its clients, needs in regard to this growing segment of ... core product database to include in-depth, fact-based orphan drug analysis ...
(Date:6/17/2013)... June 17, 2013 With the huge success ... of the Chief Medical Officer Summit for Emerging Life Science ... take place in San Francisco on November 4-5, 2013 at ... first time, West Coast Chief Medical Officers at biotechs have ... Stoner, Managing Director of MPM Capital. Valerie Bowling, Executive Director ...
(Date:6/17/2013)... MUNDELEIN, Ill. , June 17, 2013 /PRNewswire/ ... – News), a biotechnology company providing value-added ingredients ... it will be presenting a new meat application ... (IFT) show in Chicago , ... Trim ingredients can replace more expensive/chemically-modified ingredients in ...
(Date:6/17/2013)... DUBLIN , June 17, 2013 /PRNewswire/ ... http://www.researchandmarkets.com/research/9rwvs2/north_america ) has announced the addition of ... Market - by Formulations [Liposomes, Microspheres, & ... Prefilled, Pen, Needle Free & Auto Injectors] ... to their offering. ,      ...
Breaking Biology Technology:Evaluate Launches Enhanced Orphan Drug Intelligence 2Evaluate Launches Enhanced Orphan Drug Intelligence 3Chief Medical Officer Summit for Biotechs Goes West 2Chief Medical Officer Summit for Biotechs Goes West 3Z Trim to Spotlight New Meat Applications at IFT 2013 in Chicago 2Z Trim to Spotlight New Meat Applications at IFT 2013 in Chicago 3North America Injectable Drug Delivery Market - by Formulations, Devices & Therapeutics- Forecasts to 2017 2North America Injectable Drug Delivery Market - by Formulations, Devices & Therapeutics- Forecasts to 2017 3
... N.J., Dec. 17 National Stem,Cell Holding, Inc. ... financial information, quotations and press releases are,posted on ... OTCIQ is a secure, web-based portal that ... facilitate communication with the,marketplace, promote transparency, mitigate risk, ...
... Genzyme Corp.,(Nasdaq: GENZ ) announced today that ... a supplemental indication for Thyrogen(R) (thyrotropin,alfa for injection) ... ablate,or destroy, the remaining thyroid tissue in patients ... is a procedure that patients,commonly undergo when being ...
... DIEGO, Dec. 17 SGX Pharmaceuticals, Inc.,(Nasdaq: SGXP ... appointed to,the company,s Board of Directors. Mr. Turner brings ... and will also serve on,the company,s audit committee., ... said Dr. Christopher S.,Henney, Chairman of the Board of ...
Cached Biology Technology:National Stem Cell Holding, Inc. Posts Company and Financial Information on the OTCIQ and Has Retained New CFO and Counsel to File Registration Statement With SEC 2Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation 2Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation 3Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation 4SGX Pharmaceuticals Appoints Joseph L. Turner to Board of Directors 2SGX Pharmaceuticals Appoints Joseph L. Turner to Board of Directors 3
(Date:6/14/2013)... Cliffs of Dover" was a morale-boosting song that lifted ... mark the point at which England is closest to ... structures made of the chalky, white shells that envelop ... . "Ehux" is a coccolithophore, with an exoskeleton made ... the alga,s "armor" forms releases carbon dioxide, Ehux can ...
(Date:6/14/2013)... 12 June 2013: Data presented at EULAR 2013, the ... that novel antibody biomarkers could significantly improve diagnosis in ... UH-RA.1, UH-RA.9, UH-RA.14 and UH-RA.21 were investigated; as ... were present in both early and seronegative disease, ... and ACCP -negative patients testing positive. , RA ...
(Date:6/13/2013)... that combining improved oyster restoration methods with limits on ... population back to the Bay in a much shorter ... of the University of Maryland Center for Environmental Science,s ... restoration options to see which ones would have the ... we developed suggests that oysters should be able to ...
Breaking Biology News(10 mins):Chalking up a marine blooming alga: Genome fills a gap in the tree of life 2Chalking up a marine blooming alga: Genome fills a gap in the tree of life 3Chalking up a marine blooming alga: Genome fills a gap in the tree of life 4Oysters could rebound more quickly with limited fishing and improved habitat 2
... remains the subject of "best guesses," and as a ... perceptions and politics, rather than an objective assessment of ... , Simon Hay and Robert Snow (Kenya Medical Research ... been almost 40 years since the last global map ...
... be arranged along a ladder of intelligence—a sort of ... by our close relatives, the primates, all the way ... past decade, this ladder has been challenged by claims ... animals. For example, spotted hyenas establish hierarchies in which ...
... fight viruses is also involved in keeping cancer cells alive, ... The anti-viral molecule, called TBK-1, was found to be essential ... to a treatment for fighting cancer, the researchers report in ... surprise that this mechanism is involved in cancer cell survival, ...
Cached Biology News:Fishy cooperation 2Natural anti-viral enzyme helps keep cancer cells alive, researchers find 2
... IgY Antibodies Hypothetical protein FLJ20644, likely ... Protein Accession #: NP_060387.1 ... Genbank Definition: chromosome 14 open ... phosphatase subunit gene g4-1 [Homo sapiens] ...
Request Info...
Lineage cocktail 1 (lin 1) 50 tests...
Contained in EZ-Tn5™ Kits and are available separately for sequencing of an insertion site....
Biology Products: